New screening method may detect twice as many cases of ovarian cancer
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers from University College London have developed a new screening tool that can detect twice as many women with ovarian cancer as standard approaches.
Specifically, the study showed that the new method, which detects changes in CA125 levels, could detect cancer in 86% of women with invasive epithelial ovarian cancer.
CA125 is a protein biomarker in the blood of women that has been linked to ovarian cancer. A statistical test then predicts the woman's risk of having ovarian cancer.
"CA125 as a biological marker for ovarian cancer has been called into question. Our findings indicate that this can be an accurate and sensitive screening tool, when used in the context of a woman's pattern of CA125 over time," said Professor Ian Jacobs, chief investigator of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), an co-inventor of the statistical approach.
"What's normal for one woman may not be so for another. It is the change in levels of this protein that's important. My hope is that when the results of UKCTOCS are available this approach will prove capable of detecting ovarian cancer early enough to save lives."
The study evaluated 46,237 women who were screened annually for ovarian cancer over a 14-year period.
A new screening tool can detect twice as many women with ovarian cancer as standard approaches.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|